AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation

FORT WORTH, Texas–(BUSINESS WIRE)–Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®)
technology company, and AqVida, a German oncology Finished Dosage
Formulation (FDF) manufacturer, are pleased to announce today that they
have received European approval from the EDQM (European Directorate of
Quality Medicines) for AqVida’s paclitaxel injectable FDF.

Phyton Biotech is the world’s leading manufacturer of paclitaxel active
pharmaceutical ingredient (API), utilizing its prorprietary PCF®
technology process. Under the strategic partnership with AqVida, Phyton
Biotech will be the exclusive supplier of paclitaxel API for AqVida’s
Taxol generic formulation, which is produced in AqVida’s new
state-of-the-art injectable manufacturing facility located in Dassow,
Germany. AqVida’s ultramodern robotic manufacturing line, designed for
filling cytotoxic injectables, will be utilized to produce AqVida’s
generic oncology medicines to treat common types of cancer.

“We chose to work with Phyton because of the company’s superior quality
fermentation-produced API, in comparison to naturally extracted or
semi-synthetically produced alternatives,” says Wolfgang Heinze, who is
the Chief Executive Officer (CEO) of AqVida. “Approval of ourpaclitaxel
injectable FDF by the European Directorate of Quality Medicines is a
major milestone for our company.”

Recognized for its innovative and broad portfolio of generic oncology
medicines, AqVida is a leading German oncology medication supplier that
distributes its products globally.

“We are proud to partner with AqVida and assist with the expansion of
its oncology product line,” says Colin Marr, president of Phyton
Biotech. “Phyton is committed to working with trusted pharmaceutical
partners who seek to improve the quality of oncology medicines.”

About Phyton Biotech

Phyton Biotech, a wholly-owned subsidiary of DFB Pharmaceuticals, is the
global leader in Plant Cell Fermentation (PCF®) Technology, offering
comprehensive services for the development and commercialization of
plant-based molecules, extracts and recombinant products, serving the
pharmaceutical, Chinese Traditional Medicine, Cosmetic, Agricultural and
Food Ingredient industries. Using PCF®, Phyton Biotech offers a time-,
risk- and cost-balanced path to commercially viable production
processes, overcoming limitations often experienced with traditional
plant extraction and chemical synthesis.

As a biotechnology leader with certified GMP facilities in Germany and
Canada, Phyton Biotech has a successful track record of developing and
implementing innovative contract development solutions for clients
around the world. The company is now the world’s largest producer of
paclitaxel and docetaxel via PCF®, with the capacity to meet more than
one-third of the global demand for these critical active pharmaceutical
ingredients. For more information, please visit phytonbiotech.com.

About AqVida

AqVida is a German pharmaceutical manufacturer of injectable finished
dosage formulation (FDF) medications. Its mission is fully dedicated to,
and specialized in, the development, registration, manufacturing and
distribution of injectable FDF mainly for the oncology sector. It has
developed a portfolio of injectable generic oncology medicines for
treating the most common types of cancer. AqVida’s expertise in generic
oncology products has made the company a leading partner in the
pharmaceutical industry. 

Contacts

Julia Smith – Finch Media
[email protected]